SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · PPR

Synucleinopathy-like Clinical Features and Biologically Defined Synucleinopathy in Psp-parkinsonism: An Imperfect Match

· 2026-01-16

DOI: 10.21203/rs.3.rs-8470662/v1

Check source for accessPreprintOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

Abstract Whether synucleinopathy-like (syn-like) symptoms match biologically-defined synucleinopathy in PSP-parkinsonism (PSP-P) vs. Parkinson’s disease (PD) remains unexplored. We studied 80 subjects: 20 PSP-P, 20 PSP-Richardson-syndrome (PSP-RS), 20 PD, and 20 controls (CS). Procedures included specific smell-testing, structured interview by a sleep specialist, orthostatic-stress test, specific dysautonomia scale, CSF-α-synuclein seed-amplification-assay (asyn-SAA) and neurofilament-levels (NfL). Frequency of syn-like symptoms was low in CS+PSP-RS, intermediate in PSP-P, and high in PD. Premotor probable-RBD and orthostatic hypotension favoured PD, whereas probable-RBD after motor onset and higher pupillomotor dysautonomia scale scores predominated in PSP groups. NfL peaked in PSP-RS, not differing among PSP-P, PD and CS. asyn-SAA was 100% positive in PD, 100% negative in CS+PSP-RS, and positive in 24% PSP-P. Not all clinically-syn-like PSP-P cases were asyn-SAA positive, and vice versa. In summary, while partly overlapping with PD (including mild neurodegeneration as per NfL), syn-like symptoms do not always match biological synucleinopathy in PSP-P.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.